Abstract Library

#919 Effect of Combined Treatment with mTOR Inhibitors (mTORi) and Dopamine Agonists on Cell Proliferation in a Human Typical Lung Carcinoid Cell Line

Introduction: The mTOR pathway and dopamine receptors are potential targets for treatment of neuroendocrine tumors (NET).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Sarnataro M

Authors: Sarnataro M, Pivonello C, De Martino M, Sciammarella C, Cuomo G,

Keywords: mTOR, dopamine,

#850 Expression of IGF/mTOR Pathway Components in Human Pheochromocytomas and In Vitro Inhibition of PC12 rat Pheochromocytoma Cell Growth by mTOR Inhibitors alone and in Combination with the Dual IGFI-R/INS-R Antagonist OSI-906

Introduction: Dysregulation of the mTOR and IGF pathways have been suggested to be involved in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, such as sirolimus (S) and everolimus (E), as well as IGFI-R antagonists such as OSI-906, could be new a treatment for malignant PPC.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: De Martino M

Authors: De Martino M, Feelders R, Dogan F, Van Koetsveld P, De Krijger R,

Keywords: IGF, mTOR, everolimus, OSI-906, pheochromocytoma, PC12, adrenal, neuroendocrine, tumor,

#670 The Relationship Between the Ki-67 Protein and IGF-Related Genes in Gastroenteropancreatic Neuroendocrine Tumor Patients with Normal and Elevated Serum Chromogranin-A

Introduction: GEP-NETs are rare, heterogeneous neoplasms with a distinct biological and clinical behavior. Both IGF-system and Ki-67 indices have been reported as important stimulating factors in carcinogenesis and/or tumor progression. The tumor marker CgA is an independent predictor for survival as well. Currently no data are available about a possible interaction between IGF-system (IGF(-R)s, IRs, BPs) and Ki-67 protein in GEP-NET patients with normal and elevated serum CgA.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: van Adrichem R

Authors: Van Adrichem R, De Herder W, Feelders R, De Martino C, De Krijger R,

Keywords: GEP-NET,

#320 Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs

Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: De Martino M, Ducreux M, Dromain C, Duvillard P, Guigay J, Leboulleux S,

Keywords: everolimus, mTOR, RECIST, pancreas, neuroendocrine, tumor, proliferative index, predictor,

#269 Expression of IGF/mTOR Pathway Components in Human Pheochromocytomas and In Vitro Inhibition of PC12 Rat Pheochromocytoma Cell Growth by mTOR Inhibitors

Introduction: The pathogenesis of pheochromocytomas (pheo) is poorly understood and malignant pheo need new treatment options. mTOR inhibitors, as sirolimus(S) and everolimus(E), are promising antineoplastic drugs.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: De Martino M, Feelders R, van Koetsveld P, De Krijger R, Sprij-Mooij D,

Keywords: IGF, mTOR, everolimus, sirolimus, pheochromocytomas, PC12, adrenal, neuroendocrine, tumor,